Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Tidal Therapeutics
Taking full control of partner Translate Bio means that Sanofi is the only big vaccine company with a wholly-owned mRNA platform in-house but observers say it is too early to declare that the Paris-headquartered group has bagged itself a bargain.
The subdued number of acquisitions of biotech by big pharma has more than one cause. The structural improvement of the process of drug discovery and development at big pharma is the main one.
Strong sales of Dupixent and its range of vaccines are expected to drive Sanofi’s financial results for the first quarter of 2021, although these are likely to have been adversely affected by currency exchange rate movements. Numerous data readouts are expected in the coming months from pipeline products.
- Drug Delivery
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Nanotechnology, Chips, etc.